Back

Two-year outcomes of drug-coated balloon only strategy for de novo lesions in large coronary vessels

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Drug-coated balloons, stents, and scaffolds Percutaneous Coronary Intervention (PCI) ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Ryo Bando

Tokushima University Hospital, Tokushima (Japan)

5 More presentations in this session

Presentation thumbnail
Long term safety of paclitaxel coated balloon for de novo non-small coronary lesions
Doctor X. He (Galway, IE)
Abstract Slides
Presentation thumbnail
Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease intervention.
Doctor V. Tsampasian (Norwich, GB)
Abstract Slides Video
Presentation thumbnail
Drug coated balloon treatment with or without long inflation time in patients undergoing percutaneous coronary intervention: a propensity score matching analysis
Doctor Y. Fujiwara (Tenri, JP)
Abstract Slides Video
Presentation thumbnail
Incidence of restenosis after drug-coated balloon percutaneous coronary intervention in patients with diabetes mellitus - a single-centre experience
Doctor A. Hanzek (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
The impact of underlying plaque characteristics following the novel resorbable magnesium scaffold implantation: an intravascular OCT assessment up to 12-months
Doctor A. Aytekin (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Drug-coated balloons, stents, and scaffolds

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Percutaneous intervention is better than surgery in real life for most patients: pro
thumbnail
Congress Presentation
Association of PCI with outcomes in stable coronary artery disease
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources